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The ErbB signaling pathways, which regulate diverse physiological responses such as cell survival,
proliferation and motility, have been subjected to extensive molecular analysis. Nonetheless,
it remains poorly understood how different ligands induce different responses and how this is
affected by oncogenic mutations. To quantify signal ﬂow through ErbB-activated pathways we have
constructed, trained and analyzed a mass action model of immediate-early signaling involving
ErbB1–4 receptors (EGFR, HER2/Neu2, ErbB3 and ErbB4), and the MAPK and PI3K/Akt cascades.
We ﬁnd that parameter sensitivity is strongly dependent on the feature (e.g. ERK or Akt activation)
or condition (e.g. EGF or heregulin stimulation) under examination and that this context
dependence is informative with respect to mechanisms of signal propagation. Modeling predicts
log-linear ampliﬁcation so that signiﬁcant ERK and Akt activation is observed at ligand
concentrations far below the Kd for receptor binding. However, MAPK and Akt modules isolated
from the ErbB model continue to exhibit switch-like responses. Thus, key system-wide features of
ErbB signaling arise from nonlinear interaction among signaling elements, the properties of which
appear quite different in context and in isolation.
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Introduction
The ErbB1–4 receptor tyrosine kinases (RTKs) and the
signalingpathwaystheyactivate,controlcelldivision, motility
and survival and are among the best studied of all signal-
transduction networks (Citri and Yarden, 2006). Hyperactive
and aberrant ErbB signaling has been implicated in a wide
variety of human cancers and is a frequent target of
pharmaceutical intervention (Slamon, 1987; Rusch, 1993;
Engelman, 2007). ErbB1–4 receptors bind as homo- and
heterodimers to a family of 13 soluble and membrane-bound
ligands and activate multiple downstream signaling pathways,
including the mitogenic Ras-MAPK cascade and the pro-
survival PI3K/Akt pathway. Complexity arises in ErbB
networks from hetero- and homo-oligomerization among
receptors having distinct ligand-binding properties and differ-
ent intracellular binding partners, and from the multiplicity of
intracellular proteins that interact with these receptors. Awide
varietyofanti-ErbBdrugsareinuseordevelopment,including
small-molecule ATP competitors (e.g. geﬁtinib and erlotinib)
and therapeutic antibodies (e.g. cetuximab and trastuzumab),
but most drugs exhibit signiﬁcant patient-to-patient variation
in efﬁcacy (Slamon, 2001; Paez, 2004). The causes of this
variation are under active investigation (Ono, 2004; Carey,
2006; Mulloy, 2007) and appear to be multi-factorial, even at
the level of immediate-early signaling (Jasper, in preparation).
Quantitative, network-level analysis is therefore needed to
predict the consequences for signal transduction of changes in
the activities and levels of multiple proteins. Toward this end,
we have developed a computational model of the mammalian
ErbB network that includes signaling from all four receptors
and the ERK and Akt signal-transduction cascades.
ErbB receptors are single-pass type I transmembrane
receptors with extracellular ligand-binding domains, intracellular
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www.molecularsystemsbiology.comtyrosine kinase domains and cytoplasmic tails that act as
signaling scaffolds. ErbB1 and ErbB4 are fully functional as
ligand-dependent tyrosine kinases, but ErbB2 does not bind
anyknownligand,functioninginsteadasadimerization-ready
signal ampliﬁer (Klapper, 1999). ErbB3 has a crippled kinase
domain lacking catalytic activity (Guy, 1994) and therefore
transduces signals only when phosphorylated by other ErbB
receptors. The 13 known ErbB ligands can be divided into
three groups: (i) those that bind speciﬁcally to ErbB1, such as
epidermal growth factor (EGF), transforming growth factor
alpha and amphiregulin, (ii) those that bind to both ErbB1 and
ErbB4, including betacellulin, heparin-binding EGF, epigen
andepiregulinand(iii)theneuregulins(NRGs),whichfallinto
a subgroup comprising NRG1 (also known as GGF2, SMDF or
HRG) and NRG2 that binds to heterodimers containing ErbB3
or ErbB4 and a second subgroup comprising NRG3/NRG4 that
binds ErbB4 homodimers (Figure 1; Supplementary Figure
1A). Concomitant with ligand binding, ErbB receptors
dimerize and undergo trans-phosphorylation on residues in
their cytoplasmic tails thereby creating docking sites for SH2-
containing adapter molecules, such as Shc, Grb2, Sos and
PI3K.ErbB1hasatleast20sitesoftyrosinephosphorylationon
its cytoplasmic tail, 12 of which are thought to partner with
SH2-containing adapter proteins and enzymes (Schulze et al,
2005). Other ErbB receptors undergo equally extensive post-
translational modiﬁcation and adapter binding. Receptor-
associated adapters activate Ras, ERK and Akt. Akt can also
be activated in a Ras-independent manner through the direct
binding of PI3K–p85 to multiple sites on ErbB3. Key effectors
of ERK and Akt include the Elk-1, AP-1 and NF-kB transcrip-
tion factors. In addition, ErbB receptors also activate protein
kinase C, actin-based morphogenic responses and Jak–STAT
signaling, but we have not yet modeled these pathways.
Finally, the ErbB response is silenced by internalization and
degradation of receptors, dephosphorylation by phosphatases
and negative feedback from active ERK and Akt.
Figure 1 Simpliﬁed schematic representation of the ErbB model. Receptor interaction, internalization, recycling and activation of MAPK and PI3K/Akt pathways are
shown. Phosphatase, Ras-GTP hydrolysis and feedback regulation are indicated by red arrows. Matrix shows properties of each receptor dimer relevant to the topology
of the model; see Figure 1 in Supplementary information for further information. The preﬁx C on certain proteins denotes an abbreviated representation of multiple
species in the model, e.g. C:Shc is composed of all receptor-bound Shc molecules, which may include ErbB1/1-Shc, ErbB1/2-Shc and so on. However, each of these
Shc complexes is represented explicitly by one or more dynamic variables in the model.
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Yarden, 2006), in which a broad array of ligands and receptors
funnel into a limited number of core signaling cascades
(MAPK,PI3K–Akt,Jak–STATandsoon)tocontroladiverseset
of transcription factors, raises fundamental questions as to
howsignalsaretransducedfromthecell surface to the nucleus
without loss of information. This question is particularly acute
inthecaseof ErbB networks, inwhichmultiple ligands control
adiversityofphysiological responses in acell-speciﬁc manner,
although nonetheless engaging a common set of signaling
proteins. It seems probable that the ErbB network encodes
information through changes in the stoichiometry and half-
lives of post-translational modiﬁcations and thelocalization of
interacting kinases, phosphatases and so on. To begin to
understand these phenomena, we require a quantitative
framework that encompasses the diversity of receptor hetero-
and homo-oligomerization and atleast some of the complexity
of upstream ligands and downstream signaling. We also
require an effective means to incorporate experimental data
into the model in a manner that reproduces ligand- and cell-
speciﬁc responses while taking into account uncertainty in the
precise biochemistry of ErbB signaling and the inability of
experiments to measure all relevant processes. Here, we
present, as a substantial extension of our earlier work
(Schoeberl et al, 2002), an ordinary differential equation
(ODE) model of ERK and Akt regulation by two ErbB ligands
and four ErbB receptors during the immediate-early phase of
ligand-stimulated cell signaling. Relative to previously pub-
lished models of ErbB signaling (Kholodenko et al, 1999;
Hatakeyama, 2003; Resat et al, 2003; Hendriks, 2005;
Sasagawa et al, 2005; Birtwistle et al, 2007), ours is more
extensive in including all four receptors and two ligand
classes, although nonetheless retaining the rigor of a mass
action formulation based on elementary reactions. A recently
published ErbB model by Birtwistle et al (2007) is also based
on a kinetic representation of immediate-early signaling (from
0 to 30min rather than 0 to 120min as in our model), but
aggregates species to reduce complexity. In contrast, we rely
on elementary reactions throughout, albeit at the cost of more
species and parameters. We consider parametric uncertainty
and model non-identiﬁability explicitly and account for the
fact that parameter sensitivity or robustness can only be
interpreted in light of this uncertainty. Despite its non-
identiﬁability, our model predicts experimentally veriﬁable
system-wide features, such as variable ampliﬁcation in
receptor-activated enzymes as the basis of a very broad range
in dose responsiveness.
Results
To construct a computational model of ErbB-mediated signal-
ing, we extended our previous model (Schoeberl et al, 2002),
which contained only the ErbB1 receptor, using information
from models of other mammalian signal-transduction cas-
cades and a large body of newly published data (Yarden and
Sliwkowski, 2001; Citri and Yarden, 2006). Our primary goal
was expanding from a single receptor to all four members of
the ErbB family, thereby enabling analysis of receptor–recep-
tor interaction and determinants of differential signaling by
ligands such as EGF and HRG. The Immediate-early ErbB
Reaction Model (IERMv1.0) in this paper was implemented in
a deterministic, continuum approximation as a network of
ODEs with temporal coverage from 0 to 120min after ligand
addition.
Seven ErbB hetero and homodimers that have been
described in the literature were included in our model: ErbB1/
1, ErbB1/2, ErbB1/3, ErbB1/4, ErbB2/2, ErbB2/3 and ErbB2/
4. The majority of these dimers are activated by ligand
binding, but several arise through a process of ‘lateral
signaling’ (or secondary dimerization) in which dimers
phosphorylated in a ligand-dependent manner dissociate into
monomers that then reassociate with either phosphorylated or
unphosphorylated monomers to create new homo- or hetero-
dimers (Graus-Porta et al, 1997); in this way, active ErbB2/2
can form even though it is does not bind ligand. Because it has
no kinase activity and is presumably inactive (Guy, 1994),
ErbB3/3 was omitted from the model. ErbB3/4 and ErbB4/4
were also omitted because the cell lines we studied express
ErbB3 and ErbB4 at substantially lower concentrations than
ErbB1 and ErbB2 (receptor numbers for A431, H1666 and
H3255 lines are reported in Supplementary Figure 2B). Each
receptordimerspawns a cascade of downstream reactions and
omitting ErbB3/3, ErbB3/4 and ErbB4/4 reduces the total
number of species in the model by B250, making numerical
integration and parameter estimation signiﬁcantly easier.
Model scope
Two critical decisions that arise during model design involve
scope and level of detail. One point of view holds that models
should include all known components and relevant phenom-
ena so as to capture cellular biochemistry in as complete and
realistic a manner as possible. However, as the number of
proteins increases, so does the number of free parameters that
governtheirinteraction,ofteninanonlinearmanner.Asecond
pointofviewholdsthatmodelsshouldbeassimpleaspossible
as long as they reproduce empirical ﬁndings; ideally, models
should have fewer degrees of freedom than training data
(Aldridge et al, 2006). However, strict application of this
reasoning generates models in which biochemical processes
are lumped together and the functions of individual proteins
are difﬁcult to discern. In common with previous studies
(Kholodenko et al, 1999; Hatakeyama, 2003; Hendriks, 2005),
we therefore chose to model ErbB signaling at an intermediate
resolution in which key proteins were represented explicitly,
but without accounting for all assembly intermediates.
General cellular processes, such as protein degradation and
endocytosis, were represented without molecular detail as
simple ﬁrst- or second-order reactions, the rates of which were
estimated by optimization (see below). With respect to
downstream pathways, the model was restricted to ERK and
Akt because, among the many cascades induced by ErbB
ligands, both are known to be critical for mitogenesis and cell
survival. Among the 13 known ErbB ligands, EGF and
heregulin (HRG) were implemented as being representative
of two major speciﬁcity classes: EGF binds only ErbB1-
containing dimers, and HRG binds only ErbB3- and ErbB4-
containing dimers (Berkers et al, 1991; Peles, 1992; Carraway
et al, 1994). Modeling two ligands, seven receptor dimers and
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proteins. Protein–protein interactions, post-translational mod-
iﬁcations and compartmentalization involving these 28
proteins generated a total of 471 additional species that
participated in 828 reactions requiring 499 differential
equations, 201 unique reaction rates and 28 non-zero initial
conditions (species, rates and reactions can be found in
Supplementary Figure 2). Although variations in network
topology were explored in the course of model assembly, only
the ﬁnal conﬁguration is described below; it represents the
most compact description of the full ErbB receptor layer.
Future model reﬁnement is expected to focus on ensemble
approaches that attempt to resolve topological uncertainty in
the Akt pathway (Kuepfer et al, 2007), inclusion of additional
signaling cascades and more principled treatment of combi-
natorial complexity during receptor activation.
On the basis of the experiments in HeLa cells, it has been
proposed that EGF-induced expression of dual speciﬁcity
phosphatases and other ErbB-negative regulators plays an
important role in shaping the dynamics of intracellular
signaling starting B30min after ligand addition (Amit,
2007). However, when A431 or H1666 cells, which are the
focus of this study, were treated with cycloheximide (an
inhibitor of protein synthesis) no signiﬁcant difference in ERK
and Akt dynamics was observed relative to cells not treated
with cycloheximide (data not shown). Thus, we ignore the
impact of ligand-induced protein expression on the dynamics
of immediate-early signaling in the current work.
Mass action kinetics
Reactions in the ErbB model were formulated as elementary
unimolecular or bimolecular processes according to the law of
mass action, with r¼kA for a unimolecular reaction involving
protein A (where A indicates the total number of molecules of
A per cell, r a rate and k a rate constant), r¼kAB for a
bimolecular reaction involving A and B. Hill functions and
other higher order algebraic expressions were not used
because they represent approximations to cascades of ele-
mentary reactions. Thus, cooperativity, nonlinear input–out-
put behaviors and feedback arise in the model only from the
interplay of simple reactions. Protein concentrations through-
out the ErbB network were high (absolute protein num-
bersb10
3percell),sodeterministicapproacheswereused.We
have not yet considered the possible involvement of slow
reactionsorsmallreaction compartments(oo100molecules)
for which stochastic simulation might be more suitable.
Compartmentalization
Biological and reaction compartments were implemented and
both were assumed to be well mixed. The former included
compartments for plasma and endosomal membranes, cyto-
sol, nucleoplasm and lysosomal lumen. We also implemented
clathrin-mediated endocytosis as a second-order reaction in
clathrin and ErbB; this is obviously an extreme simpliﬁcation
of the actual biochemistry but does reﬂect the need forclathrin
and the receptor to interact prior to vesicular uptake. Reaction
compartments were implemented by representing a single-
gene product as multiple species each in its own well-mixed
pool and able to participate in its own set of reactions. This
made it possible to model the actions of scaffolding and
adapter proteins, the molecular details of which are unclear.
Protein transport was modeled in a computationally tractable
manner as movement of a species from one compartment to
the next with ﬁrst-order kinetics (spatial gradients and partial
differential equations were therefore avoided). In the current
model, reaction compartments were used to encode cytosolic
and membrane-bound Ras and to represent protein phospha-
tase 2A (PP2A), an enzyme that dephosphorylates Raf, MEK
and Akt in IERMv1.0 (Ugi et al, 2002). Although the model
includes only one PP2A catalytic subunit, by implementing
pools of PP2A in three separate compartments it was possible
to account for differential phosphatase activity with respect to
Raf, MEK and Akt. Differential activity presumably arises from
the association of PP2A with different regulatory subunits
(Silverstein et al, 2002), but we did not include any of these
details.
Simplifying network structure
The process of multi-site receptor phosphorylation and
recruitment of SH2-containing proteins to receptor tails
generates a ‘combinatorial explosion’ in possible species and
reactions (Hlavacek, 2003). If we assume that the 12 known
SH2-binding phospho-sites on ErbB1 are independent of each
other and exist in both phosphorylated and unphosphorylated
states, then ErbB1 monomers have 2
12¼4096 distinct states
and dimers have (4096)
2B1.6 10
7 states (Schulze et al,
2005). Careful treatment of these phospho-states is likely to be
important, as ErbB1 binds B8 distinct SH2 proteins and in
some cases, multiple SH2 domains compete for binding to a
single tyrosine residue (Jones et al, 2006). However, systema-
tic computational treatment of combinatorial complexity
places severe demands on parameter optimization because
repeated cycles of numerical integration are required (Blinov
et al, 2004). For simplicity, we therefore used a two-state
approximation in which receptors were either fully depho-
sphorylated or fully phosphorylated. The two-state assump-
tionseemsreasonable,givenexperimentaldatathatﬁveErbB1
phosphotyrosine sites (Y845, Y992, Y1045, Y1068 and Y1173)
for which assays could be established in A431 cells were
phosphorylated and dephosphorylated with similar dynamics
over a 120-min period post-EGF stimulation (data not shown).
However, the assumption is likely to break down under some
conditions(Schulzeet al,2005). Thus,ourapproachshouldbe
considered a ﬁrst step toward a more complete treatment of
receptor biochemistry as computational methods advance and
additional experimental data are collected.
Determining parameter values
ODE models are composed of initial-value differential equa-
tionsinvolvingtwotypesofparametersthatmustbemeasured
or estimated: initial species numbers (protein concentrations,
expressed in molecules per cell) given by x0,i for the ith
species,andrateconstants(forwardandreverserateconstants
for complex formation and enzymatic rate constants for
enzymes) given by kj for the jth rate. Prior to estimation, we
speciﬁed parameter values for as many x0,i and kj as possible
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measured for several key proteins in A431, H1666 and H3255
cell lines (ErbB1–4, Shc, MEK, ERK and Akt) by semiquanti-
tative immunoblotting relative to recombinant standards; our
measurements (e.g. B10
6 molecules of ErbB1 per A431 cell)
were consistent with literature estimates when available.
Receptor–ligand association constants for EGF and HRG were
obtained from published cell surface-binding assays or surface
plasmon resonance experiments performed on puriﬁed re-
ceptor ectodomains (Berkers et al, 1991; Landgraf and
Eisenberg, 2000; Stein et al, 2002). Rate constants for ErbB1/
1 and ErbB1/2 dimerization were also obtained from the
literature (Hendriks et al, 2003). Association rates for other
receptor dimers were inferred from published data describing
partnering preferences for ErbB receptors (Graus-Porta et al,
1997). Experimentally determined rates of internalization
were used for ErbB1 homodimers (Hendriks et al, 2003).
Downregulation of ErbB3 and ErbB4 was not modeled
explicitly, except for inclusion of a single tyrosine phosphatase
of unspeciﬁed identity that acted on all four receptors. We
observed that ErbB3 activation peaks and is substantially
downregulated on the order of minutes (data not shown).
Ubiquitin-mediated protein degradation has been shown to
regulate ErbB3 (Cao, 2007), but this process is on the order of
several hours, which is too slow to account for the observed
dynamics of ErbB3 phosphorylation. Further experimental
analysis of ErbB3 and ErbB4 downregulation is therefore
necessary to enable detailed modeling. The remaining class of
rate constants covered the binding of cytoplasmic proteins to
receptor tails and to partner proteins (e.g. PI3K to Gab1, MEK
to ERK). Some of these rates have been measured experimen-
tally for ErbB- or other RTK-mediated signal-transduction
systems, including the forward and reverse rates for PI3K
binding to the insulin receptor (Felder, 1993), and others have
been estimated computationally under the assumption that
translational and rotational diffusion-limited kinetics prevail
(Northrup and Erickson, 1992). On the basis of rates of related
reactions and theoretical estimates, we assumed adapter
binding to receptors to have nominal forward rates of 10
 5/
molecule/s and reverse rates of 10
 3/s on a per cell basis, as
ﬁrst described by Kholodenko et al, (1999). However, Grb2–
Sos dissociation rates were set at a value slightly lower than
nominal adapter-binding off-rates to reﬂect the experimental
observationthat the twoproteinsare constitutivelycomplexed
(Sastry, 1995).
Parameter optimization
Parameters for which good experimental cell-based estimates
are available, including Kd values for EGF receptor and HRG
receptor binding and the concentrations of experimentally
measured species were set at their measured values. Other
parameters were estimated by minimizing an objective
function (see Materials and methods) comprising the normal-
ized root mean square deviation (RMSD) between time course
data and computed model trajectories. Training data com-
prised 120 measurements collected in triplicate for pErbB1,
pAkt and pERK levels at 10 time points from 0 to 120min
following stimulation of A431, H1666 or H3255 cells with
saturating (5nM EGF or HRG) or near-physiological (10pM
EGF or 100pM HRG) ligand concentrations. Assays were
performed with phospho-speciﬁc antibodies for ErbB1-Y1068,
ERK1-T202/Y204 (ERK2-T185/Y187) and Akt-S473 as the
phosphorylation states of these kinases are known to be
reasonable proxies for activity, as well as for Shc-Y239/Y240,
which is phosphorylated by ErbB1. A431 cells were chosen
largely for their high expression of ErbB1, which ensures that
receptormodiﬁcationwaseasilymeasurable,andalsobecause
A431 cells have been the subject of many previous studies
(Gadella and Jovin, 1995; Graus-Porta et al, 1997; Jones et al,
2006). H1666 and H3255 cell lines, which carry wild-type and
mutant L858R ErbB1 receptors (Sordella et al, 2004; Tracy,
2004), respectively, were studied to ascertain whether the
IERMv1.0 model could effectively capture differing signaling
dynamics in other cell types.
On the basis of previous work with models of similar
complexity (Singer et al, 2006), we expected IERMv1.0 to be
non-identiﬁable (Melke, 2006; Gonzalez, 2007) and the
landscape of the objective function to contain multiple local
minima. This precluded parameter optimization through local
optimization methods such as Levenberg–Marquardt (Mar-
quardt, 1963) or simple measures of convergence such as
Fisher information (Rodriguez-Fernandez et al, 2006) and
instead required broad and repeated searches through para-
meter space for good ﬁts. We therefore used simulated
annealing (SA) to search across a region of parameter space
spanning 2.5 log orders above and below a priori values (as
described in Table I) (Kirkpatrick et al, 1983). By restricting
ourselves to a subset of 75 rate constants and initial conditions
with the greatest impact on the objective function (out of 229
total; as identiﬁed bysensitivity—see below), we substantially
improved the convergence of parameter optimization. SA and
similar methods have been applied widely to estimate
parameters for biochemical reaction models (Gonzalez,
2007), but not, to our knowledge, with a set of ODEs as large
as those in IERMv1.0. We tested the performance of SA using
synthetic data comprising the same measurements and time
Table I Classes of reactions and nominal values for their rates
Reaction type Forward (per cell) Reverse
EGF receptor binding
a 1.0 10
7/M/s 3.0 10
 2/s
HRG receptor binding
a 1.0 10
7/M/s 7.0 10
 2/s
Receptor dimerization
b 1.6 10
 6/molecule/s 1.6 10
 1/s
Internalization
c 1.3 10
 3/s 5.0 10
 5/s
kcat phosphorylation
d 1.0 10
 1/s —
kcat dephosphorylation
e 1.0 10
 2–1.0 10
 3/s —
Adapter binding to receptor/
protein–protein complex
formation
f
1.0 10
 5/molecule/s 1.0 10
 1/s
Grb2–Sos binding
g 7.5 10
 6/molecule/s 1.50/s
The reaction class was used to determine the values of rate constants at the start
of calibration runs. Nominal values were obtained from previously published
measurements or theoretical and computational estimates.
aBerkers et al (1991); Landgraf and Eisenberg et al (2000)
bGraus-Porta et al (1997); Hendriks et al (2003).
cFor ErbB1 homodimers, Graus-Porta et al (1997); Hendriks et al (2003).
dYun (2007).
eThe kcat of dephosphorylation was assumed to be ‘slow’ relative to off-rates of
phosphatase and target association, consistent with the assumption that the
catalytic step is rate-limiting in enzymatic reactions.
fEstimated with diffusion and geometric considerations; Northrup and Erickson
(1992); Felder (1993); Kholodenko et al (1999).
gSastry (1995).
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to A431 time course. Twenty rounds of SA were observed to
return excellent ﬁts of training data to simulation (R
240.98;
see Materials and methods and Supplementary Figure 3 for
details), showing that SA is an effective means to optimize
parameters in IERMv1.0. Even with synthetic data obtained
from a model with known parameters, SA returned ﬁts in
different areas of parameter space that were associated with
different values of the objective function. These differences
arisewhen annealing does not converge rapidly, often because
the landscape of the objective function is ﬂat in multiple
dimensions and lacks well-deﬁned minima (Brown and
Sethna, 2003), but differences that are smaller than measure-
ment error (which we estimate at ±10% in our experiments)
are not of practical signiﬁcance because they cannot be
distinguished experimentally. We therefore considered all ﬁts
having an RMSD between simulated trajectories and experi-
mental data of o0.1 as equally valid. Such ﬁts could be
recovered for actual data derived from multiple cell lines,
despite substantial differences in pErbB1, pERK and pAkt
dynamics (Figure 2A–C). However, SA with real data never
returned the near-perfect ﬁts observed with synthetic data
(Supplementary Figure 3), particularly in the case of low HRG
concentrations, suggesting the presence of errors in model
structure. We also found it difﬁcult to train the model
simultaneously to Akt dynamics at high and low EGF doses:
experiments showed a 50-fold increase in EGF concentration
from 0.01nM to 5nM to have little effect on maximal Akt
levels, but to induce different dynamics of downregulation
(Figure 2A, A431). No ﬁt has as yet reproduced this effect and
further reﬁnement of Akt biochemistry is probably necessary.
The number of identiﬁed good ﬁts was constrained by
computational demands; on average, ﬁnding one good ﬁt
required 100 annealing runs and 24h on a 100-node cluster
computer. As the amount of training data increased, so did the
numberofconstraintsontheobjectivefunction,increasingthe
pErbB1
pErk
pAkt
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k2b—ErbB1 heterodimerization
k69—PIP3 activation of Akt
k103—HRG-driven dimerization
k106—PI3K activation of PIP2 through ErbB2/3
kd119—HRG binding (reverse)
Log [k69] Log [k106] Log [k103]
Log [PP2A(II)] Log [PP2A(I)] Log [k2b]
Figure 2 Experimental and simulated dynamics for three cell lines, each treated with two concentrations of EGF and HRG. Twenty good ﬁts are shown for each cell
line. (A) A431, (B) H1666 and (C) H3255 were stimulated with 5nM or 0.01nM EGF or 5nM or 1nM HRG as indicated. Vertical axes denote normalized signals
representing the phosphorylated (and nominally active) forms of ErbB1, ERK and Akt such that the highest measured and simulated value for one signal, across all
treatment conditions, was set to 100. In each panel, the ﬁt having the lowest value of the objective function is indicated by a bold line; slightly less good ﬁts are indicated
byfaded lines. Experimental dataare indicated by dots andstandard error ofthe mean (biological triplicates) by the verticalbars. (D) Distributions of 8parametervalues
across 50 independent parameter optimization runs; parameter identities are described in more detail in Supplementary information.
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minima.However,thechallengeofparameterestimationusing
time course data is more fundamental than this. Sethna and
others have shown the process to be ‘sloppy’ so that even
‘idealandcomplete’synthetictrainingdataallowonlyasubset
of the parameters in a complex biochemical model to be
estimated (Brown and Sethna, 2003). Such parametric
uncertainty is a reality for all complex biochemical models
and remains an issue even when data are added and different
ﬁtting methods are implemented.
When different rounds of SA having similar ﬁnal goodness
of ﬁt to data (that is, RMSD o0.1) were compared, some
parameter values lay within B3-fold of their mean values,
whereas others took on the full range of values allowed in the
search(Figure2D;SupplementaryFigure4).Thisconﬁrmsour
expectationthatIERMv1.0isnon-identiﬁable.Parameterswith
similar values across multiple ﬁts are well constrained,
whereas those with widely varying values are poorly
constrained, but we have not yet recovered enough ﬁts (at a
cost of B2000 processor hours per ﬁt) to compute uncertain-
ties for individual parameters. Future implementation of
reﬁned sampling approaches such as Bayesian calibration
and Markov chain Monte Carlo methods will be required
(Vyshemirsky and Girolami, 2008).
Analyzing partially calibrated models
To ascertain whether biologically meaningful information can
be derived from the IERMv1.0 model despite its non-
identiﬁability, we examined ﬁve good ﬁts for features that
seemed to be well constrained based on parameter sampling.
For the sake of simplicity, we restrict this discussion to data
obtained from A431 cells, but similar results were obtained for
other cell lines. First, we sought to identify, by computing
normalized sensitivities, those parameters having the greatest
impact on biological outputs. The fully normalized sensitivity
(sij(t)) of the ith observable ci(t) (such as pERK levels) with
respect to a change in the jth rate constant (kj) or initial
concentration (x0,j) is given by:
sijðtÞ 
qlnðciðtÞÞ
qlnðkjÞ
ð1aÞ
sijðtÞ 
qlnðciðtÞÞ
qlnðx0;jÞ
ð1bÞ
Sensitivities were converted into time-independent quantities
by integration:
sij  
1
T
Z T
0
dt  j sijðtÞj ð2Þ
where T is the ﬁnal time point, and the absolute value of the
integrand ensures that negative and positive sensitivities do
not trivially cancel to zero under the integral. The quantity sij
measures the fractional change in the ith observable upon a
fractional change in the value of the jth parameter, normalized
by 1/T so as to obtain a time-averaged value. Outputs of
interest (ci(t)) include the trajectories of phosphorylated
ErbB1, ERK and Akt over time. These were, in general,
aggregates of multiple model species. For example, total pERK
levels are represented in IERMv1.0 by B30 differentially
bound and localized species. When local sensitivity analysis
for pErbB1, pERK and pAkt was performed on the ﬁve best ﬁts
to data from A431 cells, sij ranged from 0 to B0.8, depending
on the parameter. By plotting all pairs of sij values for all pairs
of ﬁts, correlations of R¼0.69 to 0.93 were observed (where R
is the correlation coefﬁcient; Figure3). Correlation of less than
1.0 is expected, as sensitivity is a local property dependent on
actual position in parameter space, which varies from ﬁt to ﬁt,
but the mean value of R¼0.84 implies signiﬁcant similarity in
sensitive parameters across ﬁts. We explored this issue further
using a more robust but less familiar measure of ‘regional’
sensitivity:
s
Regional
ij  
1
t2   t1
Z t2
t1
dtjsijðtÞj
*+
AVG
ð3Þ
where /ySAVG indicates an average over parameter values
lying within 10
2.5-fold above and below the parameter values
of the ﬁt. This method of calculating average local sensitivity
has been discussed previously (Cukier et al, 1973; Bentele,
2004; Mahdavi, 2007) and has two advantages over simple
sensitivity: (i) it accounts for the possibility that a ﬁt does not
precisely hit a nearby minimum due to problems with
convergence during SA and (ii) it reduces the impact on
sensitivity of small but steep irregularities in the landscape of
the objective function. Because averaging over the entire
region of parameter space was too costly computationally, we
approximated the average by randomly sampling for para-
meter space in the vicinity of the ﬁt. Sampling revealed a
power-law relationship that reached convergence at B1000
rounds(Figure4A); we therefore performed regional sampling
at 1000 points around the nominal ﬁt. Regional sensitivity of
ﬁve A431 model ﬁts showed substantial commonality in the
rank order: 8 of the 10 most sensitive parameters for EGF- or
HRG-stimulated pERK were shared across ﬁve ﬁts as were 7 of
10sensitiveparametersforpAktdynamicsacrossthreemodels
(Figure 4). Thus, even a partially calibrated and non-
identiﬁable model yields meaningful information on para-
meter sensitivities, probably because the most sensitive
parameters are among the best constrained. In the following,
we concentrated on a single good ﬁt to A431 data that had the
lowest value of the objective function after calibration.
Time, stimulus and signal dependence
of sensitivity analysis
Sensitivities are always calculated for a particular model
feature (e.g. time-integrated pERK or pAkt values) under a
particular condition (e.g. stimulation with EGF or HRG).
Correlation plots were used to determine how the identities
and rank order of parameter sensitivities depended on the
featureandcondition(Figure5).Mostsijfellclosetotheorigin,
demonstrating that only a few parameters impacted each
feature, but sensitive parameters exhibited signiﬁcant differ-
ences from one feature to the next. For example, sensitive
parameters for pERK activation by EGF or HRG stimulation
were largely shared (Figure 5A). In contrast, when factors
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B50% of the sensitive parameters lay well off the diagonal,
demonstrating independent control of Akt by the two ligands
(Figure 5B). Clustering of sensitive parameters away from the
diagonal was even more pronounced when pERK and pAkt
were compared (Figure 5C and D). Finally, differences in the
identities of highly sensitive parameters were observed for
high and low ligand concentrations and early and late time
points (Supplementary Figure 5). To conﬁrm these ﬁndings
experimentally, we selected a non-obvious differential sensi-
tivity for analysis. Modeling suggested that pAkt levels were
more sensitiveto changes in ErbB1 activity than those of pERK
(Figure 5C). We therefore measured the dose-dependent
inhibition of pERK and pAkt, in EGF-stimulated A431 cells
by the ErbB1-speciﬁc inhibitor geﬁtnib and the dual-speciﬁc
ErbB1–ErbB2 inhibitor lapatinib. When sensitivity to ErbB1
activity wasdeﬁned as the concentration of drug that inhibited
the downstream signal by 50% (IC50), we observed Akt
phosphorylation to be signiﬁcantly more sensitive to geﬁtinib
(IC50B5 10
 8M) than ERK phosphorylation
(IC50B5 10
 7M) (Figure 6A). A similar 10-fold difference
was observed with lapatinib (Figure 6B), conﬁrming our
prediction from sensitivity analysis. We therefore conclude
that parameter sensitivity in the ErbB model is critically
dependent on the choice of target observable ci(t).
The target and context dependence of parameter sensitivity
is fully consistent with elementary dynamical systems theory,
but our work shows that it is also true for physiologically
important outputs and realistic parameter sets in biochemical
models. This fact is often ignored in discussions of robustness,
inwhichitisclaimedthatparametricinsensitivityisinherently
physiologically meaningful (Morohashi, 2002). Because the
parameters sensitive for different observables or conditions
overlap only partly, the fraction of parameters that are
sensitive (42 out of 229) is signiﬁcantly greater than what
might be assumed from examining only one observable or
condition (for which 6–10 sensitive parameters is typical). For
example, although pAkt dynamics in EGF-stimulated cells are
insensitive to changes in the initial concentration of the
GTPase Ras (Figure 5B), this does not mean that the ErbB
pathway is robust to changes in Raslevels: pERK dynamics are
critically dependent on this parameter (Figure 5A, yellow
dots).
With respect to the utility of sensitivity analysis on a
partially constrained model, we note that considerable
biological insight can be obtained by comparing sensitive
parameters for different ci(t). For pERK dynamics in EGF- or
HRG-stimulated cells, the three sets of sensitive parameters
were Ras levels, on- and off-rate constants for association of
MEK and Raf, and for association of MAPK pathway
phosphatases and their targets (Figure 5A). This makes sense
biologically because both EGFand HRG activate ERK through
Ras and Raf. In contrast, the differential sensitivity of pERK to
Fit 1 0.75 0.76 0.88 0.82
Fit 2 0.69 0.79 0.88
Fit 3 0.81 0.85
Fit 4 0.85
Fit 5
pErbB1 correlation of sensitivity
0.81 0.73 0.84 0.84
0.76 0.80 0.89
0.87 0.84
0.89
pERK correlation of sensitivity
0.80 0.83 0.93 0.87
0.80 0.82 0.89
0.89 0.89
0.92
pAkt correlation of sensitivity
Fit 1
Fit 2
Fit 3
Fit 4
Fit 5
Fit 1
Fit 2
Fit 3
Fit 4
Fit 5
A
B
C
Figure 3 Correlation of sensitivities between ﬁve best A431 ﬁts that have been
optimized for parameters by simulated annealing. Panels give time-integrated
sensitivities for (A) pErbB1, (B) pERK and (C) pAkt dynamics. Within each
panel, small boxes in the lower triangle show the correlation plot for parameters
sensitivities between two ﬁts; upper triangle shows correlation value (R)
associated with each correlation plot.
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the key role played by ErbB1/1 dimers in EGF binding,
whereas the sensitivity of pERK in HRG-stimulated cells to
ErbB2andErbB3levelsreﬂectstheirrolesinHRGbinding.The
number of ligand-speciﬁc sensitive parameters for pAkt
dynamics was particularly high, revealing non-overlapping
mechanisms of Akt activation by EGF and HRG. For example,
for HRG but not EGF stimulation, on-rates of binding of PI3K–
p85 to ErbB3 receptor were critical. Intriguingly, PIP2 levels,
and rate constants for PIP3–Akt and PIP3–PTEN interaction
appearedtoplayparticularlyimportantrolesinpAktdynamics
regardless of ligand, consistent with frequent mutation of
PTEN and regulators of inositol phosphates in human cancer.
The set of sensitive parameters common to both EGF-
mediated pERK and pAkt induction was limited to GAP and
ErbB1 initial concentrations (Figure 5C). This is reasonable
given that both ERK and Akt depend on ErbB1 and Ras for
activation. In contrast, protein phosphatases appeared as
signiﬁcant off-diagonal factors, implying differential control of
the two kinases. The calibrated vmax (calculated using the
expression vmax¼kcatA, where A is the concentration of
enzyme A) for the PP2A compartment that targets pRaf and
pMEK was 1–3 orders of magnitude greater than for the
compartment targeting pAkt (data not shown). Differential
sensitivity extended to all three PP2A reaction compartments,
supporting the hypothesis that PP2A functions quite differ-
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Figure 4 Regional sensitivity analysis. Regional sensitivities were calculated according to equation (3). (A) Changes in sensitivity rankings as a function of number of
randomizationiterationsusedinsamplingforregionalsensitivity. Changesinrankingswerecalculatedrelativetotherankingsoftherun withthenextsmallestnumberof
iterations.(Inset) Power-lawrelationshipbetween rankchanges andincreasing samplesize onalog-linear scalewithan exponentof 0.4.(B–F)Regionalsensitivities of
ﬁveﬁtstoA431data,showingthetop 10sensitiveparameters forpErbB1(B),pERK(C,E)andpAkt(D,F)dynamicsintegratedovertime followingstimulationwith5nM
EGF(B–D),orHRG(E,F).Shadingofentriesisasfollows:black—parameterswitharankorderinthetop10acrossallﬁveﬁts;darkgrey—intop10acrossfourﬁts;light
grey—in top 10 across three ﬁts.
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prediction, we implemented an alternative model having only
one compartment for PP2A. In this model, pERK dynamics
deviated substantially from experimental values under condi-
tions of HRG stimulation (Supplementary Figure 6, dotted
line). However, such a comparison ignores the possibility that
a single-compartment model with an optimized set of
parameters might perform as well as the three-compartment
model. When we reﬁtted the single-compartment model using
data from A431 cells and SA, we observed substantial
improvement in goodness of ﬁt. Nonetheless, signiﬁcant
differences between single- and three-compartment models
were obtained across multiple SA runs: IERMv1.0 correctly
predicted that pERK levels would peak at 5min after HRG
stimulation before gradually declining (Supplementary Figure
6, solid line), whereas no single-compartment model returned
a ﬁt with correct timing (typically, the pERK peak was delayed
B15min in simulation relative to experiment; Supplementary
Figure 6, dashed line). The inability of SA to identify good ﬁts
to data for the single-compartment model does not constitute
proof that PP2A exists in multiple distinct states, but the
negative result is consistent with the hypotheses that depho-
sphorylation of Raf, MEK and Akt occurs at different rates,
presumably through different PP2A-containing complexes.
Moreover, our ﬁndings are consistent with previous analysis
suggesting that phosphatases play a particularly critical role in
shaping RTK signaling dynamics (Heinrich et al, 2002).From a
methodological perspective, our ﬁndings also highlight the
need to re-optimize parameters when comparing models that
differ in structure.
Network-level predictions and their experimental
conﬁrmation
An important measure of the value of a kinetic model is its
abilitytogeneratetestablepredictionsthatprovidenewinsight
into complex biochemical processes. Experimental validation
k2b—ErbB1 heterodimerization
k6—Internalization of ErbB1-containing dimers
k42—PP2A(I) deactivation of Raf
k44—Raf activation of MEK
kd68—PI3K activation of PIP2 (reverse)
k69—PIP3 activation of Akt
k103—HRG-driven dimerization
kd103—HRG-driven dimerization (reverse)
k106—PI3K activation of PIP2 through ErbB2/3
k106b—PI3K activation of PIP2 through ErbB1/1
k109—PTEN deactivation of PIP3
kd119—HRG binding (reverse)
p
p
Figure 5 Dependency of parametric sensitivity on model feature or condition. Sensitivities were calculated according to equation (1). (A–D) Correlation plots
comparing two dynamic variables (model features) or ligands (conditions). Vertical and horizontal dotted lines divide the plots into four quadrants (as labeled in red on a
yellow background): I—insensitive parameters; II–III—parameters exhibiting differential sensitivities; IV—parameters along the diagonal showing joint sensitivities.
Colors depict the biological activity or part of the pathway to which a parameter belongs as follows: red—receptor; blue—phosphatase; green—MAP kinase cascade;
purple—PI3K–Akt cascade; yellow—Ras and its regulators. (A) pERK sensitivities compared for stimulation with 5nM EGF versus HRG stimulation and (B) pAkt
sensitivities under the same conditions. pERK versus pAkt sensitivities compared under 5nM EGF (C) or HRG (D).
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example (Figure 6). The trained IERMv1.0 model also
predicted correctly the dose–response of proteins such as
pShc(Figure7A),but thisisnot astringent testofperformance
as pShc levels closely followed those of pErbB1. We therefore
turned to predicting and understanding the dose–response
behavior of the ErbB network, a fundamental measure of
biological activity that has been examined in detail by others
(Goldbeter and Koshland, 1984; Huang and Ferrell, 1996;
FerrellandMachleder,1998;Hendriksetal,2005)Twomeasures
of dose responsiveness are the ligand concentration for half
maximal activation (theEC50)andthesteepnessof the transition
from on to off, which can be described by an apparent Hill
coefﬁcient(Happ).Happiscalculatedbya nonlinearleast-squares
ﬁt of dose–response data to the Hill equation:
pSignalðxÞ¼
xHapp
xHapp þ kHapp ð4Þ
where pSignal is the normalized magnitude of signal (e.g.
ErbB1 phosphorylation), x is the concentration of input (e.g.
EGF), the free parameters Happ, k are the apparent Hill
coefﬁcient and half-maximal concentration of x. A sigmoidal
dose–response curve for a second-order ligand–receptor
interaction has k¼Kd, Happ¼1.0 such that the levels of
receptor–ligand complex rise from 10 to 90% of their maximal
value over an 81-fold change in ligand concentration. A third
useful measure of a signaling cascade is the extent of
ampliﬁcation and attenuation at successive steps:
CðEGF; tÞ¼
pSignal1ðtÞ
pSignal2ðtÞ
ð5Þ
where pSignaln refers to the activity or state of modiﬁcation of
protein n in a signaling cascade. Because all signals are
dynamic, EC50 and Happ are functions of time, which we set at
t¼5min (the peak for transient ERK and Akt responses).
Simulation across multiple ﬁts showed Happ for pERK and
pAkt as a function of EGF (equation (4)) to be B0.30 and,
unexpectedly, that both kinases would be activated to
signiﬁcant levels in A431 cells at ligand concentrations well
below the lowest reported Kd for EGF–ErbB1 association
(B0.1nM; Carraway et al, 1994). Experiments conﬁrmed this
prediction: although pErbB1 and pShc levels rose to measur-
able levels only above 10
 9M EGF, pERK and pAKT were
B20% maximal at EGF concentrations as low as B10
 12M
(Figure 7A). Thus, the relationship between ligand concentra-
tionandERKandAktactivities wasnearlylog-linearovera10
6
rangeof ligand (between 10
 14 and 10
 8M EGF; R
2B0.98 for a
log-linear ﬁt). Modeling suggests that this linearity arises
because the ErbB signaling cascade downstream of pShc acts
as a dose-dependent ampliﬁer with a peak at B10
 12M EGF
and C(EGF, t¼5min)varying between0 and30over therange
10
 12–10
 6M EGF. The prediction of dose-dependence in
C was conﬁrmed experimentally (Figure 7B; Supplementary
Figure 7B and C). These observations contrast with experi-
mental and theoretical analysis of MAPK signaling in
progesterone-stimulated Xenopus oocyctes by Huang and
Ferrell (1996) showing dose–response curves for MEK and
ERK activation to be nearly switch-likewith Happ¼1.7 for MEK
and Happ¼4.9 for ERK. In EGF signaling, we observe exactly
the opposite behavior: an input–output curve that was much
more gradual than expected for normal second-order ligand–
receptor binding.
To identify determinants of dose responsiveness, we
examined the input–output behavior of a MAPK module
isolated from IERMv1.0. Although the best IERMv1.0 ﬁt
predicted a shallow dose–response curve consistent with
experimental data (Figure 8A), the behavior of the isolated
MAPK module was consistent with results from Huang and
Ferrell in exhibiting a steep dependence of pMEK and pERKon
Raf activity (Happ¼4.6 and 6.3, respectively) (Figure 8B). This
difference can be rationalized by the fact that in the full model
(and presumably also in cells) the protein cascade leading to
ERK and MEK activation is driven by a Ras-dependent input,
the strength of which varies nonlinearly with time and ligand
dose and the cascade is therefore not at equilibrium. In the
isolated MAP kinase module, ERK and MEK are activated by a
Ras input of constant magnitude. This observation under-
scores the importance of considering signaling modules in the
contextofthelargernetworksinwhichtheyareembedded.We
therefore undertook a general search for variables that might
control pERK dose responsiveness in IERMv1.0. Starting with
an A431 model ﬁt having Happ¼2.9 (for pERK), we used Monte
Carlo sampling to explore single moves, or a succession of
B10
5 moves across a landscape of the 75 sensitive parameters
optimized during model ﬁtting. Among all possible single
moves,none decreased Happ bygreater than 10%, butsearches
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Figure 6 Differential sensitivity of pERK and pAkt to geﬁtnib treatment (A) and lapatinib treatment (B). Experimentally measured pERK (red diamonds and lines) and
pAkt (black squares and lines) 5min after EGF stimulation in A431 cells treated with inhibitor 10min prior to ligand addition. Error bars indicate standard error of the
mean.
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in reducing Happ by 1.5- to 2-fold. Remarkably, in any Monte
Carlosamplingrun involving 10
5moves,changesofonlyafew
parameters were responsible for almost all of the change in
Happ.Thisimpliesinitialdiffusivemovementacrossaregionof
parameter space having nearly constant Happ followed by a
sudden transition to a new region of space having a
substantially lower Happ value (Figure 8C). The amount of
Ras (c26), Raf–MEK association rate (k44) and MEK phospha-
tase rate (c53) were the parameters, the alteration of which
was most frequently responsible for transitions from high to
low values of Happ (Figure 8D). Moreover, when the impact of
changes in c26 in IERMv1.0 were examined in greater detail,
high Ras concentrations (10
5molecules per cell) resulted in a
steeper dose–response curve (HappB1.77), whereas low Ras
concentrations (10
3 molecules per cell) resulted in a ﬂatter
curve (HappB0.96) and a higher EC50 for EGF (Figure 8E).
Importantly, when isolated MAPK modules having high and
low c26 were compared, Happ of ERK was unchanged at B4i n
both (Figure 8F). Thus, the impact of c26 on MAP signaling is
restricted to settings in which the module is embedded in a
larger signaling network. Similar results were obtained with
Raf–MEK association rates (k44) (Figure 8G and H). From
these data, we conclude that the input–output behavior of the
MAPKcascadeisstronglydependenton thecontextinwhichit
is found: varying c26 and k44 in the context of the full
IERMv1.0 changes EC50 and Happ, but varying the same
parameters in an isolated cascade has virtually no effect.
Parametric sensitivity in input–output responses is something
we might anticipate from the properties of electronic ﬁlters and
a m p l i ﬁ e r s ,b u ti th a sn o tp r e v i o u s l yb e e ne x p l o r e di nc e l l
signaling. The preceding analysis implies, however, that we
should observe considerable diversity from one cell type to the
next with respect to the EC50 and Happ for Akt and ERK. In four
cancer cell lines (AU565, HBL100, MCF7 and T47D), pErbB1
activation exhibited a narrow range of EC50 values (10
 8–10
 9M
EGF) and HappB1.0. In contrast, Happ for pERK and pAkt was
much more variable, ranging from 0.58 to 1.61 (Figure 9A) and
EC50 values were spread over 10
 9–10
 12ME G F( F i g u r e9 B ) .
These data are consistent with the biochemistry of the ErbB
signaling network. Activation of ErbB1, which is most upstream
and governed only by the kinetics and thermodynamics of EGF–
receptor interaction and the biochemistryof the kinase domain, is
expected to be similar across cell lines. In contrast, signals further
down the cascade are modulated by many upstream proteins,
many of whose concentrations and rate constants impact EC50
and Happ. We therefore conclude that the diversity of dose–re-
sponses that can be generated by simulation (using different sets
of parameter values) also occurs in real cells. We speculate that
this behavior confers great adaptability on ErbB signaling and
helps to explain its importance in manyaspects of cell physiology.
Discussion
In this paper, we describe the construction of an ODE-based
model of immediate-early signaling involving all four ErbB
receptors, analysis of parameter sensitivity and uncertainty
and exploration of factors controlling overall input–output
behavior. The IERMv1.0 represents ErbB receptors and down-
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Figure 7 (A) Dose–response of pErbB1, pShc, pERK and pAkt (5min after ligand
addition)overa10
6rangeofEGFconcentrationsinA431cells.(B)AmpliﬁcationCof
signal calculated with equation (5) (5min after ligand addition) over a 10
6 range of
EGFconcentrationsinA431cellsforpERK,pAktandpShc.Pointsrepresentdataand
lines represent simulation; error bars denote standard error of the mean. Gray boxes
show high error measurements at low EGF concentrations, which arise due to
phospho-ErbB1 signals being at the limit of detection.
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of MAPK module
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of MAPK module
Monte carlo trajectory Distributions of parameters 
affecting Happ
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Figure 8 (A) Dose–response of pERK (red line) and pErbB1 (black line) computed with best IERMv1.0 ﬁt to A431 data. (B) pERK (red line) and pMEK (blue line)
responses in a MAPK module isolated from IERMv1.0. (C) Apparent Hill coefﬁcient Happ (as deﬁned using equation (4) in text) of pERK during Monte Carlo sampling of
parameters. (D) Parameters controlling apparent Hill coefﬁcient: c44—Raf phosphatase abundance; k48—phosphatase binding to MEK; c41—Raf abundance; kd49—
phosphatase catalysis of MEK; c53—MEK phosphatase abundance; c26––Ras abundance; k44––Raf binding to MEK. (E) Dose–response of pERK for an IERMv1.0 ﬁt
with high Ras (parameter c26) abundance (dotted line) or low Ras (solid line). (F) Dose–response of pMEK (blue line) and pERK (red line) in a MAPK module isolated
from a IERMv1.0 ﬁt having low values of parameter c26 (left panel) or high values (right panel). (G) Dose–response of pERK for an IERMv1.0 ﬁt with high k44 (dotted
line) or low k44 (solid line). (H) Dose–response of pMEK (blue line) and pERK (red line) in a MAPK module isolated from an IERMv1.0 ﬁt having low values of k44 (left
panel) or high values (right panel).
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interactions among elementary species are encoded in a
continuum mass action approximation by ﬁrst- and second-
order elementary reactions. Our model has the merit of
explicitly capturing interactions among multiple ErbB recep-
tors and ligands, as well as downstream events such as Ras
activation and MAPK and PI3K–Akt signaling, without use of
complex functions, quasi-static state Michaelis–Menten ap-
proximations and aggregation of biochemically distinct
species. Complex behaviors arise in the model from interac-
tions among simple elementary reactions, making it possible
to explore (through sensitivity analysis) the functions of
individual species on input–output behavior and to predict the
effects of RNAi, small-molecule drugs and mutations. We
explore the ﬁrst topic in this paper and the others in a
forthcoming paper on the determinants of cellular sensitivity
to anti-ErbB1 drugs (Jasper, in preparation). Forsimplicity, the
current model omits several signaling pathways activated by
ErbB receptors and lacks a rigorous treatment of the web of
reaction intermediates arising from protein assembly (e.g.
SH2-containing proteins). In futurework,it should be possible
to extend IERMv1.0 to include additional downstream signal-
ing pathways and upstream ligands. However, thorough
treatment of interactions among 13 ligands, 4 ErbB receptors
and 8–12 adapters will require both conceptual and technical
advances in modeling reaction networks (Hlavacek, 2003;
Danos et al, 2007).
Our representation of immediate-early ErbB signaling
involves a large number of free parameters, but with respect
to scope and level of detail IERMv1.0 is not atypical of other
recent efforts to model cell signaling (Kholodenko et al, 1999;
Hatakeyama, 2003; Hendriks, 2005). Sensitivity analysis
shows that the behavior of IERMv1.0 is dependent on the
values of many rate constants and initial protein concentra-
tions that have not been measured directly. Moreover, even
whenin vitro biochemicaldataareavailable, their relevanceto
the crowded environment of a cell is unclear (Schnell and
Turner, 2004). Thus, many signiﬁcant parameters must be
estimated by ﬁtting; biochemical data on isolated proteins are
most useful, in this context, as a means to initiate or constrain
the search (e.g. Table I). Over a series of B2000 independent
parameter optimization runs involving searches across B10
6
parameter sets, we found only B100 (0.01%) that had a good
ﬁt to data (RMSDo0.1), implying that the search landscape is
very rugged and deep minima are infrequent, Moreover,
among equally good ﬁts (those that varied by less than
experimental error), only a subset of parameter values were
constant, whereas others varied over the entire allowable
range. Thus, IERMv1.0 is non-identiﬁable and we presume
that large regions of parameter space are consistent with
experimentally observed dynamics. One interpretation of this
ﬁnding is that biological networks are so robust to changes in
rate constants and protein concentrations (von Dassow et al,
2000)thatparametricuncertainty isnotasigniﬁcantissue:key
physiologicalbehaviors,inthisview,aredeterminedprimarily
by pathway structure. The other extreme view is that complex
models with unconstrained parameters have little practical
value, as any behavior can be achieved with suitable
adjustment of parameters. We have demonstrated that neither
of these extremes is true: physiologically important aspects of
ErbB signaling such as the dose responsiveness are indeed
determined by the values of speciﬁc parameters, but useful
and accurate predictions can be made using partially
constrained models.
Model identiﬁability and parametric uncertainty
Model identiﬁability is a subtle issue for which a wide variety
of analytical and numerical methods have been developed.
Figure 9 (A) Experimentally determined dose–response of pErbB1 (upper
panel), pERK(central panel)and pAkt(lower panel) att¼5min acrossa range of
EGFconcentrations inmultiple cancercelllines.Hill coefﬁcientsfor eachEC50as
calculated by nonlinear regression are given in the legend. (B)E C 10—effective
concentration at 10% of maximum—of three signals for each cell line. Boxes
indicate the position of the EC10. Data points and ﬁts to a Hill curve (lines) are
colored as follows: black—AU565; red—HBL100; green—MCF7; blue—T47D.
The levels of pErbB1 in MCF7 were below the level of detection, but activation of
ERK and Akt signals in response to EGF treatment was easily measured. Hill
coefﬁcients as calculated by nonlinear regression for activation of pErbB1, pERK
and pAkt are, respectively, in AU565 cells, 1.36, 0.82 and 0.58; HBL100 cells,
1.20, 0.89 and 0.88; T47D cells, 1.18, 1.61 and 1.02. For MCF7 cells, Hill
coefﬁcientsforactivationofpERKandpAktwere,respectively,1.53and1.03.(B)
EC10—effective concentration for 10% maximal activation for three phospho-
signals ineach cell line (box). Colored lines above boxes indicate the width of the
corresponding activation proﬁle of the Hill curve, deﬁned as the concentration
range that spans a rise in activation from 10 to 90%.
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are presented as though they have a single parameter
solution set. In the area of biochemical or pathway models,
published identiﬁability analysis has focused on analytic
approaches to small idealized models (Margaria et al,
2001; White, 2001). Parameter estimation for large models
such as IERMv1.0 involves numerical and Monte Carlo
approaches such as SA (van Riel, 2006; Gonzalez, 2007).
In general, parameter estimation has four possible
outcomes (White, 2001): (i) a single, unique, parameter
solution set, making the model fully identiﬁable, (ii) a
countable number of parameter sets, making the model
‘locally identiﬁable’, (iii) an inﬁnite number of solution
sets, making the model non-identiﬁable and (iv) no solution
sets, in which case the model probably has structural
ﬂaws. Parameter optimization with IERMv1.0 conforms to
possibility (iii).
Non-identiﬁability of our model arises in part because
the quantity, quality and type of data are inadequate
and relationships among parameters and experimental ob-
servables are inherently non-unique (Hengl et al, 2007).
Why then, do we not simply double or triple the amount
of data used for model training? Unfortunately, it has been
shown that even a complete set of time-resolved measure-
ments of all species in a complex reaction model is insufﬁcient
to fully constrain all parameters due to the ‘sloppy’ nature of
the ﬁtting procedure (Gutenkunst, 2007). It is likely that
experiments can be designed to mitigate some of this
sloppiness, but the necessary design and ﬁtting methods
have not yet been developed. Thus, non-identiﬁability is
likely to remain an issue for all complex biochemical
models. Methods such as ensemble modeling and
parameter sampling have been developed to cope with non-
identiﬁability in ﬁelds as diverse as climate and nuclear
reaction modeling (Christie et al, 2005). Means to sample
parameters have also been applied to models of Drosophila
melanogaster segment polarity (Ingolia, 2004) and mTOR
signaling (Kuepfer et al, 2007). However, the issue of
identiﬁability is widely ignored in biological modeling. It
would be valuable to know which parameters are well
constrained, which co-vary and which are truly uncon-
strained. The width of the distribution in parameter values
across repeated rounds of SA serves as a proxy for this
parametric uncertainty (Figure 5E), but the small number of
good ﬁts available for the ErbB model prevents our deriving
reliable estimates for individual parameters. Nonetheless, it is
clear that some parameters are much better constrained than
others (e.g. phosphatase levels were tightly distributed across
multiple parameter optimization runs but many receptor
dimerization rates assumed a wide range of values). In
principle, it is legitimate to draw conclusions based on well-
constrained parameters despite the presence of other uncon-
strained variables. We approximate this ideal by comparing
features across multiple ﬁts. We anticipate that future
implementation of SA, genetic and hybrid algorithms that
take advantage of modularity or branch-and-bound (Singer
etal,2006)willimproveourunderstandingofparameterspace
and thus of parametric uncertainty. It will then be possible to
generatepredictionsfrommodelswithquantiﬁableconﬁdence
or signiﬁcance.
Parameter sensitivity and robustness
Sensitivity analysis is a straightforward and informative
means to determine which features of a model have the
greatest impact on a particular output or model feature. When
we evaluated parameter sensitivity in regions of parameter
space centered on independent ﬁts (Cukier et al, 1973), we
observed the rank order of the most sensitive parameters to be
relatively constant and thus, relatively unaffected by para-
metric uncertainty. However, we also found the identities of
the most sensitive parameters to be highly dependent on the
output being evaluated. Thus, sensitive parameters for ERK
versus Akt, or high versus low ligand concentration or HRG
versus EGF are frequently distinct. The union of sensitive
parameters across all features and conditions encompasses a
much larger fraction of the total parameters in the IERMv1.0
model than sensitivity to a single feature. This conclusion
contradictstheoft-citedstatementthatbiologicalpathwaysare
insensitive to variation in parameter values, but is congruent
with experience in other ﬁelds of dynamical systems theory.
Moreover, it emphasizes the fallacy of simply equating
‘robustness’ of a network with parametric insensitivity.
Response duration might be insensitive to changes in
parameter P but dose–response relationships might be highly
sensitive; as we cannot a priori claim that only the former is
physiologically important, we cannot state that the network is
robust to variation in P. Where it possible to enumerate all
physiologically signiﬁcant features of the ErbB pathway in
developmentornormalcyversusdisease,wespeculatethatthe
majority of parameters would prove sensitive under one
condition or another. Thus, analysis of robustness is inter-
pretable only with respect to speciﬁc physiological behaviors.
Behaviors that arecommon to manycell types and tovariation
in initial conditions hint at a much more interesting type of
robustness in ‘design’ that we have yet to understand.
Input–output responses of the ErbB network
as revealed by modeling and experiment
ToascertainwhetherIERMv1.0canpredictsigniﬁcantnetwork
features not included in the training data, we examined input–
output relationships for EGF and pERK or pAkt. Detailed
analysis of progesterone-mediated ERK activation in Xenopus
oocytes (Huang and Ferrell, 1996) has revealed ultrasensitive
behavior (Goldbeter and Koshland, 1984) and a high Hill
coefﬁcient arising from double phosphorylation of ERK by
MEK and from positive feedback (Huang and Ferrell, 1996;
Brown et al, 1997; Ferrell and Machleder, 1998). We were
therefore surprised to ﬁnd that, over a 10
6 range in EGF
concentrations, our model predicted low Hill coefﬁcients
(Happ¼0.32) and experiments conﬁrmed this prediction. As a
consequence, ERK was B20% as highly phosphorylated at
10
 12M EGFas at B10
 7M (a saturating level). Ampliﬁcation
of signal at low doses of EGF (as implied by Happo1) may help
to explain why many ErbB-targeted drugs inhibit receptors at
signiﬁcantly lower drug concentrations than they inhibit
downstream kinases: a small number of active receptors are
sufﬁcient to drive a substantial downstream signal.
The multivariate nature of control over Happ in IERMv1.0
makes it challenging to understand mechanistically, but it is
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the coupling of Ras, Raf and MEK play a major role in setting
dose responsiveness of a receptor-driven MAPK cascade. It
should be noted, however, that dose responsiveness is more
complex than we have implied hitherto, as it has an important
temporalcomponent; Raf activationdynamics, forexample, are
predicted to change dramatically as EGF concentrations
increases (a prediction we have been unable to test due to poor
antibody speciﬁcity; Supplementary Figure 7D). Further study
of these phenomena will require the development of suitable
descriptors of time-varying transfer properties in cell signaling
cascades. Moreover, it will undoubtedly prove interesting to
compare ourdata-driven approachwithrecent theoretical work
on network biology (Saez-Rodriguez et al, 2004; Del Vecchio
etal,2008).Theclearsuggestionisthatthecouplingofmodules
under particular conditions (high retroactivity or mismatched
impedanceattheconnections)resultsinnetworks,thebehavior
of which cannot be easily predicted from analysis of the
modules in isolation.
Summary and future prospects
Two aspirations motivate the construction and analysis of
complex kinetic models: elucidating the roles of individual
proteins at the level of speciﬁc biochemical reactions and
determining how sets of proteins work together to create
modules with discrete physiological functions. We have
shown progress in both of these areas for a biochemically
realistic model of immediate-early ErbB signaling trained
against dynamic data. The strong contextual dependency of
parameter sensitivity emphasizes that protein activity is
meaningful only with respect to a particular physiological
function: many parameters that are insensitive under one set
of physiologically reasonable conditions are highly sensitive
under another. This is also true at the level of network
modules. Although the Raf–MEK–Erk signaling cascade has a
switch-like input–output behavior in isolation, within the
context of the ErbB pathway the apparent Hill coefﬁcient is
B10-foldlowerandtheresponseislog-linear.Thus,wecannot
generalize from thebehaviorof a signaling module in isolation
to its behavior in a biological network. These are valuable
insights with respect to our initial aspirations, but emphasize
the importance of developing methods to estimate parameter
values and handle parametric uncertainty through optimal
experimentaldesignandBayesianestimation.Thechallengeis
now to implement these concepts in a practical manner with a
complex biochemical model.
Materials and methods
Model implementation
TheErbBmodelwasimplemented intwo softwarepackages: MATLAB
and Jacobian. In MATLAB (MathWorks, Natick, MA), the model was
constructed using the Simbiology Tool Box, comprising 828 reactions,
499speciesand201parameters.Themodelwasalsoreimplementedin
Jacobian,areaction-engineeringprogramfromNumerica(Cambridge,
MA). The numerical integrator in Jacobian is optimized for sparse
systemssuchastheErbBmodel.Themodelisavailableinﬁveformats,
(i)SBML,(ii)MATLABSimbiologyobject,(iii)asetofJacobianscripts,
(iv)a setoftextﬁlesofreactions,speciesandparametersor (v)asa set
of text ﬁles of ODE equations, initial conditions and parameters
(http://www.cdpcenter.org/data/Chen_2008, model ﬁles). Model
dynamics on MATLAB and Jacobian platforms were shown to be
consistent.
Sensitivity analysis
Local sensitivity analysis was performed with Jacobian. Sensitivities
were fully normalized as in equation (1). Regional sensitivity, deﬁned
as an ‘average’ sensitivity of a parameter around a ﬁt in parameter
space, involved repeated rounds of sensitivity calculation and
averaging of the value. In each run, all parameters are randomly
modulated around the nominal values. We calculated regional
sensitivities only in the Jacobian package, because sampling is
computationally intensive and Jacobian’s numerical solver was able
to calculate more samples. Sensitivity averaging and parameter
modulation was implemented in Jacobian’s scripting environment.
For parameter modulation, each nominal parameter was multipliedby
a different, random factor of 10
x where x is a random number evenly
distributed between  2.5 and 2.5. This gives rise to a model with new
parameter values that deviate from nominal ones. The sensitivity of a
parameter is calculated for this new model, and entered into the
average. This process is repeated a thousand times, and the resulting
average sensitivity across randomly parameterized models gives the
regional sensitivity.
Simulated annealing
SA was implemented in the scripting environment of Jacobian. The
conﬁguration space is given by the vector of parameter values. The
‘energy’ function is given by the RMSD function that assigns a score to
each conﬁguration is the objective function, deﬁned as follows:
U ¼
X Nexpt
i¼1
X Nobs
j¼1
X Nt
k¼1
ðxi;jðtkÞ xe
i;jðtkÞÞ
2
where x is the number of activated molecules of some species in the
model, x
e is the number of activated molecules of the corresponding
species in experiment, Nobs is the number of measurables or
observable species, Nexpt is the number of experimental conditions
and Nt is the number of time points in the experiment. The measured
phosphorylation of a species was normalized for each cell line such
that the maximum signal for a species among all stimulation
conditions was set to 1 (in Figure 2, the signals are further scaled to
reach 100). The simulated dynamics for pERK and pAkt were
normalized by dividing by the maximal possible activated signal (the
initial number of molecules of the unphosphorylated form). For
simulated pErbB1, the maximalpossibleactivated signalwas assumed
to be 70% of the measured number of ErbB1 molecules, as we
observed that with higher ligand concentrations, more ErbB1
activation could be observed (data not shown). The normalization
conditions for ERK and Akt reﬂect the assumption that the maximal
observed signal is a ‘saturating’ one, i.e. all species have been
phosphorylated. The objective function measures how well a model
with a particular conﬁguration of parameters is able to produce
dynamics-matching experiment. Of the 201 rate constants and 28
initial protein species numbers, 75 moves are possible (see main text).
The move at each iteration of SA in parameter space consists of a
multiplicativechangeinaselectedparameter,wherethemultiplicative
factor (or move size) is 10
x where x is a random increment of 0.25.
Acceptance of a move is given by the Metropolis criterion, i.e. if the
move results in a decrease in the objective function, the move is
accepted; if the move results in an increase in the objective function,
the probability that a move is accepted is given by e DE=T, where DE is
the change in objection function value after the move. We set bounds
on the moves, so parameters did not deviate more than 10
2.5-o r
10
 2.5-fold from the starting point of annealing. These bounds put
limits on the size of the explored space. Cooling of the system adhered
to an exponential schedule T¼T0exp( step/step0), where T0 is the
starting temperature, step is the step number in the 4000-step
annealing run and step0 is the time it takes for the temperature to be
reduced by a factor 1/e (i.e. analogous to the half-life). Through trial
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the highest number of near optimal ﬁts.
Tissue culture
A431, H1666 and H3255 cell lines were grown in ACL-4 medium,
HBL100 and MCF7 were grown in DMEM medium, and T47D and
AU565weregrowninRPMImedium.Eachmediumwassupplemented
with 10% fetal bovine serum (FBS). Cells were trypsinized and
subcultured into 96-well plates (cat. no. 165305; Nalgene Nunc,
Rochester, NY, for in-cell western blot assays and cat. no. 3072; Becton
Dickinson, Lincoln Park, NJ, for xMAP assays) at varying densities,
grown for 24h and subsequently serum starved for 16h in the
appropriate medium containing 0.1% FBS. At the time of treatment,
the conﬂuency of all cell lines was approximately 75%.
Time course measurements by in-cell western blot
assay
Time course measurements were performed by in-cell western blot
assay. Cells were stimulated by adding ligand for the indicated length
of time. At the time of observation, ligand was removed and cells were
ﬁxed (4% formaldehyde in 1  PBS, 20min at 251C), permeabilized
(0.1% Triton in 1  PBS, four washes for 5min each at 251C with
rotation) and blocked (0.5  Odyssey Blocking Buffer (OBB) (Licor
Biosciences, Lincoln, NE), 1h at 251C with rotation). Primary
antibodies were diluted 1:100 in 0.5  OBB (50ml per well) and
allowed to incubate overnight at 41C. Cells werethenwashed 3  with
1  PBS-Tween (0.1%)for5minat251C withrotation, followedbythe
addition of secondary antibody (diluted 1:800 in 0.5  OBB) and TO-
PRO-3(DNA stain,diluted 1:2500 in0.5  OBB) andincubationfor1h
at 251C. Following three additional wash cycles, wells were aspirated
dry and scanned using the Licor Odyssey Scanner (Licor Biosciences).
Data were normalized on a ‘per cell’ basis by dividing ﬂuorescence on
the 800 channel (pErbB1, pERK or pAkt) by the 700 channel (DNA
stain).
IC50 and EC50 measurements by xMAP assay
EC50 and IC50 measurements were performed by bead-based immu-
noassay. For IC50 measurements, cells were pretreated for 1h with the
indicated concentrations of Iressa or Lapatinib (LC Laboratories,
Woburn, MA). EGF was added at 5nM for the IC50 measurements or at
the indicated concentrations for the EC50 measurements. After 5-min
incubations, the cells were washed and lysed using the Bio-Plex cell
lysis kit (Bio-Rad, Hercules, CA). pAkt (S473) and pERK (Y185/Y187)
were measured using xMAP bead kits (LHO0101 and LHO0241;
Invitrogen, Carlsbad, CA) and pY-ErbB1 was measured using Luminex
bead kit (71935-3; EMD Chemicals Inc., San Diego, CA). Assays were
performed using the Bio-Plex Phosphoprotein Detection Reagent kit
(Bio-Rad) and the Bio-Plex 200 platform (Bio-Rad).
Antibodies
Primary monoclonal antibodies recognizing pErbB1 (Y1068) (cat. no.
2234), pERK 1 (T202/Y204) or pERK2 (T185/Y187) (cat. no. 4377),
pAkt (S473) (cat. no. 4058) and MEK (S221) (cat. no. 2338) were
obtained from Cell Signaling Technology (Danvers, MA). Primary
monoclonal antibody recognizing Shc-Y239/Y240 (cat. no. 44–830)
was obtained from Biosource (now Invitrogen). Primary polyclonal
antibodies recognizing ErbB1 phosphotyrosine sites Y845 (cat. no.
2237), Y992 (cat. no. 2234), Y1045 (cat. no. 2235), Y1068 (cat. no.
4404) and Y1173 cat. no. 2231 were obtained from Cell Signaling
Technology. IRDye 800-conjugated goat-anti-rabbit secondary anti-
bodies were obtained from Rockland Immunochemicals, Gilbertsville,
PA, and TO-PRO-3 DNA dye was obtained from Invitrogen.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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